Lena Group is an international professional congress organiser, founded in 1960 as Publi Créations and an IAPCO member since 2003. With eight offices worldwide — Budapest, Florence, Istanbul, London, Milan, Monaco, New York and Tokyo — the group designs scientific meetings, educational programmes and conference communications on five continents.
Monaco and London are the two offices working on EBROW + RTI 2027: the organising and sponsors’ secretariat, and the local participants’ secretariat.
Lena Corporation S.A.M.
74 Boulevard d’Italie, 98000 Monaco
+377 97 97 35 55
Lena-UK Ltd. — Tobacco Quay
Wapping Lane, London E1W 2SF
+44 (0) 207 177 0777
These two offices are delivering EBROW + RTI 2027. Lena Group also operates in Budapest, Florence, Istanbul, Milan, New York and Tokyo.
Lena-UK Ltd. is registered in England and Wales as Shared Ideas Ltd., Company No. 14499933.
Programme logistics, faculty support and on-site delivery for international congresses.
Partnership packages, exhibition and industry relations for EBROW + RTI 2027.
Registration operations, accommodation windows and attendee communications.
Monaco headquarters with a London secretariat at Tobacco Quay, Wapping.
All official conference email will come from info@bronchiectasis-rti.org or an @lenagroup.net address. Treat anything else as suspicious. When in doubt, use the contact details on this page — never send payment or passport scans to an unexpected sender.
Michal Shteinberg is heading the bronchiectasis and adult CF service in the Pulmonology institute and CF center, Carmel medical center, Haifa, Israel. She is a Clinical Assistant Professor in the Faculty of medicine at the Technion, Israel Institute of Technology. Her main research interests are bronchiectasis and its overlap with other airway diseases, and adult CF.
Head of the Pulmonology Service at Hospital Clínic de Barcelona and accredited researcher in the IDIBAPS group Inflammation and Repair in Respiratory Diseases. His work focuses on airway infection, inflammation and bronchiectasis, including frequent-exacerbator phenotypes in the EMBARC registry.
He coordinates educational programmes on bronchiectasis at Hospital Clínic and publishes widely on mucins, inhaled therapies and treatable traits in chronic airway disease.
Natalie Lorent works as a consultant in Respiratory Medicine/Clinical Infectiology at the University Hospital Leuven where since 2015 she coordinates the care for adults with respiratory infections, bronchiectasis (CF and non-CF) and primary ciliary dyskinesia. She is involved in clinical and translational research in bronchiectasis and mycobacterial infections.
She is founder and president of the national NTM Consilium, a clinical advisory board and basis of a national registry; she chairs the European NTM research network (NTMnet) and the Belgian MDRTB expert group. She has been involved in EMBARC since the start. Natalie is also assistant professor at KU Leuven.
Felix C. Ringshausen is a board-certified physician for respiratory medicine and infectious diseases and head of the Adult Bronchiectasis and Cystic Fibrosis Service at the Hannover Medical School, Germany. In addition, he is principal investigator of the German Center for Lung Research (DZL).
His research interests are focused on European multidisciplinary networks and multicenter initiatives in order to promote clinically orientated research and improve patient care in the field of rare, neglected and under-researched aspects of respiratory infections like bronchiectasis, nontuberculous mycobacteria, respiratory viruses and adult cystic fibrosis.
Professor of Respiratory Medicine, Humanitas University, Milan, Italy. Consultant, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan.
Co-chair of the European Bronchiectasis Network (EMBARC). Chair of IRIDE, the Italian Registry of adult bronchiectasis. Chair of the Italian Registry on Non-Tuberculous Mycobacteria (IRENE).
Professor Michael Loebinger is Professor of Practice at Imperial College London and Director of the Lung Division and Deputy Medical Director at Royal Brompton Hospital. He co-chaired the British Thoracic Society bronchiectasis guidelines and co-wrote the BTS Non-Tuberculous Mycobacteria and European Respiratory Society bronchiectasis guidelines.
He is a founding member of the UK and European clinical and research bronchiectasis and NTM networks and has authored over 200 publications. He has helped design and lead multiple global clinical trials in bronchiectasis and NTM and was chief investigator for the first mRNA trials in primary ciliary dyskinesia.
Charles Haworth is a Respiratory Consultant working within the Cambridge Centre for Lung Infection at Royal Papworth Hospital where he specialises in treating adults with bronchiectasis, non-tuberculous mycobacterial (NTM) infections and cystic fibrosis.
He co-authored the British Thoracic Society Bronchiectasis clinical guidelines published in 2017 and the European Respiratory Society Bronchiectasis clinical guidelines published 2019.
He was also senior author of the International Cystic Fibrosis NTM guidelines published in 2015 and first author of the British Thoracic Society NTM guidelines published in 2017.
Between 2018–2021 he was a founding and executive committee member of the UK Cystic Fibrosis Medical Association.
In June 2024 he was invited to join the Board of the European Cystic Fibrosis Society.
Rhodes Chair of Experimental Therapeutics and Clinical Pharmacology, University of Oxford.
Chief Editor of the European Respiratory Journal.
Chair of the European Bronchiectasis Network (EMBARC).
Chair of the Standards of Care Committee of the British Thoracic Society.